MedicarePartD.guide

A non-government resource built from CMS public data

TNF blockers on every 2026 Tennessee Part D plan

Pick a drug class, or type the drugs you want to check, and see which of the 12 stand-alone Part D plans in Tennessee cover each one, on what tier, and with what restrictions.

A class overrides typed names. Separate names with commas; brand or generic both work.

  • Covered
  • Covered, needs prior authorization (PA) or step therapy (ST)
  • Not on the formulary
  • QL 60/30d = quantity limit, 60 units per 30 days

12 plans, cheapest premium first. Scroll sideways for all of them →

TNF blockers by 2026 Tennessee Part D plan
DrugHumana Basic Rx Plan$0.00/moS5884-106Wellcare Value Script$3.60/moS4802-147Wellcare Classic$3.70/moS4802-071Humana Value Rx Plan$37.70/moS5884-191AARP Medicare Rx Saver from UHC$63.20/moS5921-357BlueRx Essential$76.20/moS1030-006HealthSpring Extra Rx$77.50/moS5617-362HealthSpring Assurance Rx$87.20/moS5617-220SilverScript Choice$97.30/moS5601-024Humana Premier Rx Plan$108.60/moS5884-158AARP Medicare Rx Preferred from UHC$119.30/moS5921-393BlueRx Enhanced Plus$129.50/moS1030-001
HumiraadalimumabNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredTier 5PA25%QL 52/365dNot coveredNot coveredNot covered
adalimumab biosimilarsadalimumab-adaz, -fkjp, -aacf and othersTier 5PA25%QL 0.2/28dTier 5PA25%QL 4/28dTier 5PA25%QL 4/28dTier 5PA26%QL 0.2/28dTier 5PA25%Not coveredNot coveredNot coveredNot coveredTier 5PA33%QL 0.2/28dTier 5PA31%Not covered
Hadlimaadalimumab-bwwdNot coveredNot coveredNot coveredNot coveredNot coveredTier 5PA25%QL 2.4/28dTier 5PA25%QL 2.4/28dTier 5PA25%QL 2.4/28dTier 5PA25%QL 22.4/365dNot coveredNot coveredTier 5PA31%QL 2.4/28d
Hyrimozadalimumab-adazNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Cyltezoadalimumab-adbmNot coveredTier 5PA25%QL 4/28dTier 5PA25%QL 4/28dNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Simlandiadalimumab-ryvkNot coveredNot coveredNot coveredNot coveredNot coveredTier 5PA25%QL 3/28dNot coveredNot coveredNot coveredNot coveredNot coveredTier 5PA31%QL 3/28d
Yuflymaadalimumab-aatyNot coveredTier 5PA25%QL 2/28dTier 5PA25%QL 2/28dNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Amjevitaadalimumab-attoNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
EnbreletanerceptTier 5PA25%QL 8/28dTier 5PA25%QL 8/28dTier 5PA25%QL 8/28dTier 5PA26%QL 8/28dTier 5PA25%QL 4/28dTier 5PA25%QL 2/28dTier 5PA25%QL 8/28dTier 5PA25%QL 8/28dTier 5PA25%QL 8/28dTier 5PA33%QL 8/28dTier 5PA31%QL 4/28dTier 5PA31%QL 2/28d
Cimziacertolizumab pegolNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
SimponigolimumabNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered

Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.